Login to Your Account

Taurx completes $135M financing round to back phIII tau-targeting therapy

By Michael Fitzhugh
Staff Writer

Thursday, October 8, 2015

Taurx Therapeutics Ltd. closed a $135 million equity financing that will support completion and analysis of phase III trials of the tau aggregation inhibitor, called LMT-X, in Alzheimer's disease.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription